Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:27:56 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SEEL - SEELOS THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SEEL - Q0.10.2857·0.37250.50.291+0.00541.9562.21425790.2947  0.2999  0.28149.8498  0.281Apr 26Mar 1915 min RT 2¢

Recent Trades - Last 10 of 579
Time ETExPriceChangeVolume
19:41:44Q0.29110.00552
19:37:52Q0.2910.005422
19:29:52Q0.2980.01242,552
19:29:32Q0.2930.0074337
18:03:53Q0.2920.0064600
17:15:46Q0.290.0044177
17:15:46Q0.290.0044177
17:15:25Q0.290.0044250
17:14:56Q0.290.0044250
16:53:32Q0.290.0044300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-19 08:15U:SEELNews ReleaseSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
2024-01-26 08:30U:SEELNews ReleaseSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
2024-01-22 08:00U:SEELNews ReleaseSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
2024-01-02 08:00U:SEELNews ReleaseLeading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
2023-12-22 08:00U:SEELNews ReleaseSeelos Therapeutics, Inc. Releases Letter to its Stockholders
2023-12-01 16:00U:SEELNews ReleaseSeelos Therapeutics Announces Closing of Public Offering
2023-11-28 21:26U:SEELNews ReleaseSeelos Therapeutics Announces Pricing of $5.55 Million Public Offering
2023-11-28 16:06U:SEELNews ReleaseSeelos Therapeutics Announces Proposed Public Offering
2023-11-27 08:00U:SEELNews ReleaseSeelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
2023-11-24 10:53U:SEELNews ReleaseSeelos Therapeutics Announces 1-for-30 Reverse Stock Split
2023-10-27 08:11U:SEELNews ReleaseSeelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
2023-10-17 08:00U:SEELNews ReleaseSeelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
2023-09-27 08:00U:SEELNews ReleaseSeelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
2023-09-21 09:00U:SEELNews ReleaseSeelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
2023-09-20 07:00U:SEELNews ReleaseSeelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
2023-08-14 08:00U:SEELNews ReleaseSeelos Therapeutics Provides Second Quarter 2023 Clinical Update
2023-06-22 08:00U:SEELNews ReleaseSeelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
2023-05-22 08:00U:SEELNews ReleaseSeelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
2023-05-15 08:00U:SEELNews ReleaseSeelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
2023-05-05 08:00U:SEELNews ReleaseSeelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting